Bevacizumab, Pemetrexed and Cisplatin, or Erlotinib and Bevacizumab for Advanced Non-Squamous NSCLC Stratified by Status. A Multicenter Phase II Trial Including Biopsy at Progression (BIO-PRO Trial)

Trial Profile

Bevacizumab, Pemetrexed and Cisplatin, or Erlotinib and Bevacizumab for Advanced Non-Squamous NSCLC Stratified by Status. A Multicenter Phase II Trial Including Biopsy at Progression (BIO-PRO Trial)

Completed
Phase of Trial: Phase II

Latest Information Update: 18 Oct 2017

At a glance

  • Drugs Bevacizumab (Primary) ; Cisplatin (Primary) ; Erlotinib (Primary) ; Pemetrexed (Primary)
  • Indications Non-small cell lung cancer
  • Focus Therapeutic Use
  • Acronyms BIO-PRO
  • Most Recent Events

    • 18 Oct 2017 Results of gene expression analysis assessing genes predictive for clinical outcomes (PFS and OS) by Nanostring system using (n=99) patient samples from this trial, presented at the 18th World Conference on Lung Cancer.
    • 14 Jun 2016 Status changed from active, no longer recruiting to completed.
    • 01 Apr 2016 Results comparing two cohorts (Bevacizumab + pemetrexed versus pemetrexed alone cohort, n = 129) published in the Journal of Thoracic Oncology.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top